Australia Clears $40B Kenvue Deal, Orders Carefree and Stayfree Divestment
KMB sits 16% above its 52-week low of $92.42.
Summary
Australia's ACCC approved Kimberly-Clark's $40B acquisition of Kenvue, but requires divesting Kenvue's Carefree and Stayfree period care brands in Australia to preserve competition. Kimberly-Clark will sell Kenvue's Australian period-care brands. This is a significant regulatory milestone for the deal, which was announced in November and is also under EU review. The divestment condition is modest relative to the overall transaction and addresses a specific overlap in period care products. The approval removes a key hurdle and signals progress toward closing, though EU and other regulatory clearances remain. The deal would add major brands like Listerine and Neutrogena to Kimberly-Clark's portfolio.
At the time of this announcement, KMB was trading at $107.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $92.42 to $131.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.